30 closest matches · ranked by relevance
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Breast Cancer · Brain Tumor - Metastatic
Primary: CNS Objective Response Rate (ORR) — 5; 14; 0 percentage of participants
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Breast Cancer · Breast Neoplasms, Male · Carcinoma, Ductal
Primary: Overall Tumor Response — 1; 8; 14; 9 participants
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants
Breast Cancer
Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants
Breast Cancer · Breast Neoplasms · Cancer of the Breast
Primary: Time to Disease Progression (Initial Treatment) — 9.28; 8.88 months — p=0.385
Breast Cancer
Primary: Bone Scan Response Rate — 38.5 percentage of participants
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
Brain Metastases · Breast Cancer · Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Breast Cancer
Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 7.3; 9.4; 7.5; 10 month
Breast Cancer
Primary: Confirmed Response Rate — 0.67 proportion of patients
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Breast Cancer
Primary: Progression Free Survival — 103; 81 Days
Hormone Receptor Positive Malignant Neoplasm of Breast · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Estrogen Receptor Positive Breast Cancer
Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants
Breast Cancer
Primary: Progression-free Survival — 16 Months
Breast Cancer
Primary: Response Rate — 21 participants
Breast Cancer
Primary: Six-month Progression-free Survival (PFS) Rate at 6 Months — 39 percentage of patients
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage